Liang and Li developed selective, substrate-competitive, and passive membrane permeable GSK-3β inhibitors based on the 6-C-glycosylflavone isoorientin (22, Table 1) as valuable chemical probes and drug leads with therapeutic potential to tackle AD and other GSK-3β relevant diseases. The gene discussed is GSK3B; the disease is Alzheimer disease.